DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

A number of other brokerages also recently weighed in on DBVT. HC Wainwright raised their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Tuesday, December 10th.

DBV Technologies Stock Up 29.8 %

Shares of NASDAQ DBVT opened at $4.97 on Thursday. The stock’s 50-day simple moving average is $3.32 and its two-hundred day simple moving average is $3.83. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.49. The firm has a market capitalization of $102.23 million, a P/E ratio of -1.10 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.